http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Press+Releases/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html <p align="justify">TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with advanced AI solutions for clinical trial optimization and precision medicine, today announced its participation in the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Florida, from May 26 - 29, 2026.</p> <p align="justify">NetraMark’s Founder, Dr. Joseph Geraci, PhD, will contribute to a plenary panel discussion on artificial intelligence in psychiatry. The Company will also present two scientific posters demonstrating the application of its http://www.streetinsider.com/Globe+Newswire/NetraMark+to+Present+at+the+American+Society+of+Clinical+Psychopharmacology+Annual+Meeting/26524598.html Wed, 20 May 2026 07:00:00 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Press+Releases/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html <p align="justify">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) </strong>a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting key accomplishments during its second fiscal quarter ended March 31, 2026, as well as subsequent developments.</p> <p align="justify">During the second quarter, NetraMark continued to advance its commercial, scientific, regulatory and capital markets objectives, while further positioning its proprietary NetraAI platform as a differentiated technology for clinical trial enrichment, patient stratification, http://www.streetinsider.com/Globe+Newswire/NetraMark+Provides+Second+Quarter+Update+and+Highlights+Continued+Commercial%2C+Scientific%2C+Regulatory+and+Capital+Markets+Momentum/26496368.html Thu, 14 May 2026 17:00:00 -0400 A.03039617 AIAI AINMF O.03180664 O.52416069 PF0 http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html <p>NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) announced that Lawrence Guy has resigned from the company's board of directors, effective May 7, 2026, for personal reasons.</p> <p>The artificial intelligence company, which develops machine learning solutions for pharmaceutical and clinical research industries, stated that its board and management thanked Guy for his service and contributions to the company.</p> <p>NetraMark focuses on analyzing complex patient datasets and identifying subgroups of individuals across multiple variables simultaneously through its proprietary mathematically augmented learning system. The company's technology is designed to reveal structure in clinical trial populations and support the development of insights for disease http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html Thu, 07 May 2026 16:30:27 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html <p>NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) announced that Lawrence Guy has resigned from the company's board of directors, effective May 7, 2026, for personal reasons.</p> <p>The artificial intelligence company, which develops machine learning solutions for pharmaceutical and clinical research industries, stated that its board and management thanked Guy for his service and contributions to the company.</p> <p>NetraMark focuses on analyzing complex patient datasets and identifying subgroups of individuals across multiple variables simultaneously through its proprietary mathematically augmented learning system. The company's technology is designed to reveal structure in clinical trial populations and support the development of insights for disease http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html Thu, 07 May 2026 16:30:27 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html <p>NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) announced that Lawrence Guy has resigned from the company's board of directors, effective May 7, 2026, for personal reasons.</p> <p>The artificial intelligence company, which develops machine learning solutions for pharmaceutical and clinical research industries, stated that its board and management thanked Guy for his service and contributions to the company.</p> <p>NetraMark focuses on analyzing complex patient datasets and identifying subgroups of individuals across multiple variables simultaneously through its proprietary mathematically augmented learning system. The company's technology is designed to reveal structure in clinical trial populations and support the development of insights for disease http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html Thu, 07 May 2026 16:30:27 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html <p>NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) announced that Lawrence Guy has resigned from the company's board of directors, effective May 7, 2026, for personal reasons.</p> <p>The artificial intelligence company, which develops machine learning solutions for pharmaceutical and clinical research industries, stated that its board and management thanked Guy for his service and contributions to the company.</p> <p>NetraMark focuses on analyzing complex patient datasets and identifying subgroups of individuals across multiple variables simultaneously through its proprietary mathematically augmented learning system. The company's technology is designed to reveal structure in clinical trial populations and support the development of insights for disease http://www.streetinsider.com/Board+Changes/NetraMark+director+Lawrence+Guy+resigns+from+board/26454132.html Thu, 07 May 2026 16:30:27 -0400 AIAI AINMF O.52416069 PF0 http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Change+To+Board+Of+Directors/26454125.html <p align="justify" style="padding-left:0pt;">TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- <strong>NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)</strong>, a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy has resigned from the Company’s Board of Directors, effective May 7, 2026, for personal reasons.</p> <p align="justify">The Board and management of NetraMark thank Mr. Guy for his service and contributions to the Company and wish him well in his future endeavours.</p> <p><strong>About NetraMark</strong></p> <p align="justify" style="padding-left:0pt;">NetraMark is a company focused on http://www.streetinsider.com/Press+Releases/NetraMark+Announces+Change+To+Board+Of+Directors/26454125.html Thu, 07 May 2026 16:30:00 -0400 AIAI AINMF O.52416069 PF0